Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. - Wikidata - awgldk - TriplyDB

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

http://www.wikidata.org/entity/Q33535682

about

Emerging and future therapies for hemophilia Future of coagulation factor replacement therapy Dangerous liaisons: how the immune system deals with factor VIII Animal models of hemophilia Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors Haemophilia management: time to get personal?A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models.Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant Noncovalent stabilization of the factor VIII A2 domain enhances efficacy in hemophilia A mouse vascular injury models.Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy.The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes.PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice.Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.Advanced therapies for the treatment of hemophilia: future perspectives.New treatments in hemophilia: insights for the clinician.Engineering Factor Viii for Hemophilia Gene Therapy.Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.Allometry of factor VIII and informed scaling of next-generation therapeutic proteins.Comparison of human coagulation factor VIII expression directed by cytomegalovirus and mammary gland-specific promoters in HC11 cells and transgenic mice Molecular approaches for improved clotting factors for hemophilia.Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.Nonlinear pharmacokinetics of factor VIII and its phosphatidylinositol lipidic complex in hemophilia A mice.Acquired factor VIII deficiency: two case reports and a review of literature.The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia.Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia.Joint protection in haemophilia.The hope and reality of long-acting hemophilia products.PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.The future of hemostasis management.Will gene therapy trump factor treatment in hemophilia?New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies.Investigational drugs for coagulation disorders.Blood Clotting Factor VIII: From Evolution to Therapy.

P2860

Q26781143-0C7BB475-C24F-449A-B704-E9C3AB1DE2B4 Q26820824-76F5C6CE-7DC6-4F65-88F8-24DC5434FCD1 Q27000818-944F51CB-2ABE-4182-802A-A57786D5442C Q27012571-B0CDAD2A-53D9-4B08-80F2-9985EBBF86F8 Q28079890-48A4677F-C8D3-44B1-BA7A-1CF643190773 Q30403530-A631FE6B-C4A1-447E-96FF-A7FB4D01C2C5 Q30426130-2ECC9588-B044-457D-A56A-ED602147C212 Q30539596-9C7F80DE-0CCB-4BAD-8835-E3218828528F Q33917215-83EC60B7-55B7-413B-B499-9A3A6F24C264 Q34045763-622364F0-172A-49C1-B82F-67D7FEA91C23 Q34165592-6588F8BE-D182-469E-A979-20B548225822 Q34876876-34E0D07A-07DE-4D70-B2A8-B152F39FDF7B Q35306206-E9B4559E-805A-40E1-B989-38A42902A5EB Q35578480-510A8409-2286-453E-AD44-2C34A4C362A6 Q35612397-B8D4FA0C-FC38-493C-B189-76E0B62A962B Q35793113-37FEE1DE-9376-4330-A519-72446640585A Q35913495-044BF053-9049-4319-9AB6-62F4EB426053 Q36250957-9CD8D67B-52D7-4D2A-AE91-1D8BE3E7D636 Q36552555-A0AA767F-7437-413B-BAA0-1E386D9CE30C Q36612681-B96916D0-B2DC-492B-B054-1AA1D6B6A064 Q36737263-48521A94-32A8-4106-8BDB-BF200A553C23 Q36863328-A2E73EBE-E25D-4C03-8393-779D6EBE687D Q36912731-170581B1-45D2-468F-B6E2-9790006F7919 Q36956171-19819188-0E50-4144-A591-3C33BC250CEF Q37334700-B169BDF4-ACC7-452D-8C69-042242441CBA Q37489013-E514877D-F0DD-451B-A672-B8D6102EFE50 Q37591484-1F2711AB-464E-451D-B805-FFA050FAB8C3 Q37634856-E1FB6B2E-5D73-43FF-A778-C5B4AF80E0D7 Q37686530-C8398D0C-5D1F-402D-9D06-434E80FB5397 Q37720949-D19BE7D5-A728-42B8-9479-05101B494A52 Q37790614-1629D57F-C7E2-4C6F-A344-723AB3DFDD09 Q37845930-2B74E729-72FF-4FA8-A12D-7E47A28A0979 Q37912258-123575DC-F697-4AFA-A852-50FE8635B719 Q37990479-CD9A8540-2479-406B-A2A2-AB56C2E5C9D7 Q38036746-C8217D4F-A58D-41BF-8DC2-025F01016860 Q38056457-73C5EA1D-CCC4-41B9-9D1A-AAC99420839A Q38078426-B96E0E44-D4C5-4229-AD34-630EEE62E89E Q38104413-018EE89D-BA23-44EB-8B00-A39457A0827A Q38106245-95A91FE4-C010-4380-9CE8-C91099247912 Q38118763-91482236-6FDA-4829-B13A-871C79D192A3

P2860

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.

http://www.wikidata.org/entity/Q33535682

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Rational design of a fully act ...... II for hemophilia A treatment.

@ast

Rational design of a fully act ...... II for hemophilia A treatment.

@en

Rational design of a fully act ...... II for hemophilia A treatment.

@nl

type

label

Rational design of a fully act ...... II for hemophilia A treatment.

@ast

Rational design of a fully act ...... II for hemophilia A treatment.

@en

Rational design of a fully act ...... II for hemophilia A treatment.

@nl

prefLabel

Rational design of a fully act ...... II for hemophilia A treatment.

@ast

Rational design of a fully act ...... II for hemophilia A treatment.

@en

Rational design of a fully act ...... II for hemophilia A treatment.

@nl

P1433

Q33535682-64A7B052-04D2-4161-9FE0-CFB0D390D643

P1476

Q33535682-513EA5CC-88D7-4AA3-9A96-1FC86DF35F37

P2093

Q33535682-0B528D0F-75D1-4DBE-AC09-43B2DFE06DF8

Q33535682-0F36B3A4-B7FD-4DE4-A59A-11B78FF55B88

Q33535682-1410881E-74A4-4BB0-A121-F08A5DA15C1C

Q33535682-15D3BC77-4B1B-4496-BDF1-CDF7DEAA07D7

Q33535682-27BC9D93-749A-44ED-B197-0FD2740947F7

Q33535682-2C83B9A3-B5BD-42DB-92EE-71D00B59DEE6

Q33535682-3BEE19DE-FB27-4F0F-BCC5-8B231DA82DD3

Q33535682-76952A7F-FABB-4AB2-B314-3A73145D9087

Q33535682-77D7E170-67F3-4115-A653-8EC1A18B8DA2

Q33535682-84A54DBF-A7F1-467A-8F8B-21F4646A5006

P304

Q33535682-0B4354EC-C111-43BF-B52E-1079DCA2AD41

P31

Q33535682-BA948A20-8367-4ABD-A01F-1C836FCB32F4

P356

Q33535682-053B2FA5-EF23-4EC5-ADFD-A8216C365075

P407

Q33535682-DA1D329E-62D6-457B-BFE9-6A4C06D46393

P433

Q33535682-C4F2048F-7A49-44A8-99E6-30CC49AB047A

P478

Q33535682-1FE81FFF-BC4F-49DD-99D4-7002F81FC0E4

P50

Q33535682-7D356D1C-4E36-433B-8A94-27C7317FADBB

P577

Q33535682-FE07D40F-5FAF-4B8E-B28C-74C2B99F5C3A

P5875

Q33535682-2408F4F0-017E-464B-8B74-B77CD179BB2B

P698

Q33535682-92C07EAB-B5DA-40C4-AB8F-A6E439CF54F2

P921

Q33535682-597F3F26-FB40-4069-B474-5851AD497B00

Q33535682-B1D47A57-B0B4-4C2F-8EE6-5CB2DB6DBB00

Q33535682-E24F1679-700F-4BD4-84B9-C0DAA3FF709F

P356

BLOOD-2009-11-254755

P1433

P1476

Rational design of a fully act ...... II for hemophilia A treatment.

@en

P2093

Babu Subramanyam

http://www.w3.org/2001/XMLSchema#string

Baisong Mei

http://www.w3.org/2001/XMLSchema#string

Clark Pan

http://www.w3.org/2001/XMLSchema#string

Glenn F Pierce

http://www.w3.org/2001/XMLSchema#string

Hendri Tjandra

http://www.w3.org/2001/XMLSchema#string

Jian-Ming Gu

http://www.w3.org/2001/XMLSchema#string

Jianmin Chen

http://www.w3.org/2001/XMLSchema#string

Jim Newgren

http://www.w3.org/2001/XMLSchema#string

Joanne Severs

http://www.w3.org/2001/XMLSchema#string

John E Murphy

http://www.w3.org/2001/XMLSchema#string

P304

270-279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-11-254755

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41656976

http://www.w3.org/2001/XMLSchema#string

P698

20194895

http://www.w3.org/2001/XMLSchema#string

P921

Coagulation factor VIII